We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Test Developed for Hepatitis C Infections

By LabMedica International staff writers
Posted on 16 Apr 2018
Print article
Image: The Genedrive PCR diagnostics platform (Photo courtesy of Genedrive).
Image: The Genedrive PCR diagnostics platform (Photo courtesy of Genedrive).
A rapid, point-of-care PCR-based diagnostic test will allow for the detection of occult hepatitis C virus (HCV) infections under both laboratory and field conditions.

Chronic infection with the hepatitis C virus affects approximately 1% of the global population (an estimated 71 million people) and claims about 400,000 lives every year. PCR screening for the disease requires dedicated infrastructure and qualified staff. In countries with limited resources, this type of assay is only available in centralized laboratories. Therefore, a major clinical challenge remains to identify undiagnosed patients worldwide, many of whom live in low-income and middle-income countries, where access to nucleic acid testing remains limited. The aim of the current project was to develop and validate a point-of-care (POC) assay for the qualitative detection of HCV RNA.

For this endeavor, investigators at the Pasteur Institute (Paris, France) developed a POC assay for the qualitative detection of HCV RNA on the PCR Genedrive instrument. The Genedrive instrument is a 600-gram portable device that can be battery operated, thus making it highly suitable for decentralized testing in field settings, and requires only 30 microliters of sample.

The investigators validated the Genedrive one hour HCV assay through a case–control study comparing results with those obtained with the Abbott RealTime HCV test.

Results revealed that the Genedrive PoC assay identified all major HCV genotypes, with a limit of detection of 2362 IU/milliliter. Assessing 422 patients chronically infected with HCV and 503 controls negative for anti-HCV and HCV RNA, the Genedrive HCV assay showed 98.6% sensitivity and 100% specificity to HCV.

The Genedrive HCV diagnostic kit has obtained CE certification for distribution in Europe and will be available for sale in the Middle East, Africa, South-East Asia, and India once local regulatory clearance is obtained.

The study was published in the April 3, 2018, online edition of the journal Gut.

Related Links:
Pasteur Institute
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more